27 October 2020

• NIH announces that it is halting a trial of the Eli Lily neutralizing antibody, bamlanivimab, in people hospitalized with COVID-19 because it had no benefit in this group; studies of the antibody as prevention in long-term care facilities, and in people with recently-diagnosed and mild-to-moderate cases of COVID-19 will continue. Source
• France reports a weekly total of over 241,000 coronavirus cases. Source

Return to the timeline